| Symbol | ACTU |
|---|---|
| Name | ACTUATE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1751 RIVER RUN,SUITE 400, FORT WORTH, Texas, 76107, United States |
| Telephone | +1 817 - 887-8455 |
| Fax | — |
| — | |
| Website | https://www.actuatetherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001652935 |
| Description | Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). Additional info from NASDAQ: |
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
Read moreActuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
Read moreDirector Zabrowski Dan 🟢 acquired 15.0K shares (1 derivative) of ACTUATE THERAPEUTICS, INC. (ACTU) at $2.42 Transaction Date: May 21, 2026 | Filing ID: 004260
Read moreDirector THOMSON TODD S 🟢 acquired 15.0K shares (1 derivative) of ACTUATE THERAPEUTICS, INC. (ACTU) at $2.42 Transaction Date: May 21, 2026 | Filing ID: 004257
Read moreDirector Sawhney Roger 🟢 acquired 15.0K shares (1 derivative) of ACTUATE THERAPEUTICS, INC. (ACTU) at $2.42 Transaction Date: May 21, 2026 | Filing ID: 004255
Read moreDirector RONNEBERG AMY L 🟢 acquired 15.0K shares (1 derivative) of ACTUATE THERAPEUTICS, INC. (ACTU) at $2.42 Transaction Date: May 21, 2026 | Filing ID: 004251
Read moreDirector Keyes Jason A 🟢 acquired 15.0K shares (1 derivative) of ACTUATE THERAPEUTICS, INC. (ACTU) at $2.42 Transaction Date: May 21, 2026 | Filing ID: 004245
Read moreDirector Huber Martin H. Jr. 🟢 acquired 15.0K shares (1 derivative) of ACTUATE THERAPEUTICS, INC. (ACTU) at $2.42 Transaction Date: May 21, 2026 | Filing ID: 004243
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04832438 | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland … | Phase2 | Salivary Gland Carcinoma | Withdrawn | 2030-12-18 | 2034-06-18 | ClinicalTrials.gov |
| NCT07714395 | Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants Wi… | Phase1 | Advanced Malignant Solid Tumor | Not_Yet_Recruiting | 2026-10-01 | 2029-12-01 | ClinicalTrials.gov |
| NCT06015607 | Testing of GripTract-GI Endoscopic Tissue Manipulator for Use During Complex En… | Na | Polyps Colorectal | Recruiting | 2026-06-11 | 2027-08-01 | ClinicalTrials.gov |
| NCT06896188 | 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With… | Phase1 | Pancreatic Adenocarcinoma | Recruiting | 2025-09-22 | 2028-12-31 | ClinicalTrials.gov |
| NCT05077800 | FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer | Phase2 | Pancreatic Adenocarcinoma | Active_Not_Recruiting | 2022-03-21 | 2026-12-31 | ClinicalTrials.gov |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Phase2 | Soft Tissue Sarcoma | Withdrawn | 2022-03-01 | 2030-08-01 | ClinicalTrials.gov |
| NCT05239182 | 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Adva… | Phase2 | Pancreatic Adenocarcinoma | Terminated | 2022-01-26 | 2024-02-04 | ClinicalTrials.gov |
| NCT05010629 | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | Phase2 | Salivary Gland Cancer | Active_Not_Recruiting | 2021-09-14 | 2027-04-12 | ClinicalTrials.gov |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults… | Phase2 | Sarcoma | Withdrawn | 2021-09-01 | 2025-07-01 | ClinicalTrials.gov |
| NCT04218071 | Actuate 1901: 9-ING-41 in Myelofibrosis | Phase2 | Myelofibrosis | Completed | 2020-08-20 | 2024-01-18 | ClinicalTrials.gov |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Phase1 | Refractory Cancer | Terminated | 2020-06-05 | 2025-07-07 | ClinicalTrials.gov |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | Phase2 | Cancer | Active_Not_Recruiting | 2019-01-04 | 2026-06-01 | ClinicalTrials.gov |
| NCT03066895 | BGS Neonatal Pilot Study | Na | Pain From Heel Sticks | Completed | 2017-11-06 | 2020-09-01 | ClinicalTrials.gov |
| NCT02947646 | Feasibility of BabyGentleStick- Adult Pilot Study | Na | Lack of Adverse Events | Completed | 2016-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02724631 | TubeClear® Evaluation in Pediatric Patients (Phase I) | Na | Enteral Nutrition | Terminated | 2016-11-01 | 2020-07-07 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Elraglusib Oral Tablets | Other | Phase PHASE1 | Advanced Malignant Solid Tumor | NOT_YET_RECRUITING | NCT07714395 |
| GripTract | Other | Approved | Polyps Colorectal | RECRUITING | NCT06015607 |
| Control (via ESD using standard of care) | Other | Approved | Polyps Colorectal | RECRUITING | NCT06015607 |
| GripTract | Other | Approved | Polyps Colorectal | RECRUITING | NCT06015607 |
| Control (via ESD using standard of care) | Other | Approved | Polyps Colorectal | RECRUITING | NCT06015607 |
| Standard Lancing Device | Device | Approved | Pain From Heel Sticks | COMPLETED | NCT03066895 |
| BabyGentleStick | Other | Approved | Pain From Heel Sticks | COMPLETED | NCT03066895 |
| Standard Lancing Device | Device | Approved | Pain From Heel Sticks | COMPLETED | NCT03066895 |
| BabyGentleStick | Other | Approved | Pain From Heel Sticks | COMPLETED | NCT03066895 |
| 9-ING-41 | Other | Phase PHASE2 | Sarcoma | WITHDRAWN | NCT04906876 |
| Docetaxel | Other | Phase PHASE2 | Sarcoma | WITHDRAWN | NCT04906876 |
| Gemcitabine | Other | Phase PHASE2 | Sarcoma | WITHDRAWN | NCT04906876 |
| Docetaxel | Other | Phase PHASE2 | Soft Tissue Sarcoma | WITHDRAWN | NCT05116800 |
| 9-ING-41 | Other | Phase PHASE2 | Soft Tissue Sarcoma | WITHDRAWN | NCT05116800 |
| Gemcitabine | Other | Phase PHASE2 | Soft Tissue Sarcoma | WITHDRAWN | NCT05116800 |
| BabyGentleStick™ OFF | Other | Approved | Lack of Adverse Events | COMPLETED | NCT02947646 |
| BabyGentleStick™ ON | Other | Approved | Lack of Adverse Events | COMPLETED | NCT02947646 |
| BabyGentleStick™ OFF | Other | Approved | Lack of Adverse Events | COMPLETED | NCT02947646 |
| BabyGentleStick™ ON | Other | Approved | Lack of Adverse Events | COMPLETED | NCT02947646 |
| 9-ING-41 | Other | Phase PHASE2 | Myelofibrosis | COMPLETED | NCT04218071 |
| Ruxolitinib | Other | Phase PHASE2 | Myelofibrosis | COMPLETED | NCT04218071 |
| TubeClear® intervention | Other | Approved | Enteral Nutrition | TERMINATED | NCT02724631 |
| TubeClear® intervention | Other | Approved | Enteral Nutrition | TERMINATED | NCT02724631 |
| Carboplatin | Other | Phase PHASE2 | Salivary Gland Cancer | ACTIVE_NOT_RECRUITING | NCT05010629 |
| 9-ING-41 | Other | Phase PHASE2 | Salivary Gland Cancer | ACTIVE_NOT_RECRUITING | NCT05010629 |
| Abraxane | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | TERMINATED | NCT05239182 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | TERMINATED | NCT05239182 |
| Retifanlimab | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | TERMINATED | NCT05239182 |
| 9-ING-41 | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | TERMINATED | NCT05239182 |
| Topotecan | Other | Phase PHASE1 | Refractory Cancer | TERMINATED | NCT04239092 |
| Cyclophosphamide | Other | Phase PHASE1 | Refractory Cancer | TERMINATED | NCT04239092 |
| Temozolomide | Other | Phase PHASE1 | Refractory Cancer | TERMINATED | NCT04239092 |
| Irinotecan | Other | Phase PHASE1 | Refractory Cancer | TERMINATED | NCT04239092 |
| 9-ING-41 | Other | Phase PHASE1 | Refractory Cancer | TERMINATED | NCT04239092 |
| 9-ING-41 | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05077800 |
| Losartan | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05077800 |
| FOLFIRNINOX | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05077800 |
| 9-ING-41 | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | RECRUITING | NCT06896188 |
| Chemotherapy | Drug | Phase PHASE1 | Pancreatic Adenocarcinoma | RECRUITING | NCT06896188 |
| Retifanlimab | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | RECRUITING | NCT06896188 |
| Irinotecan | Other | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Gemcitabine - 28 day cycle | Other | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Paclitaxel. | Other | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Nab paclitaxel. | Other | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Carboplatin. | Other | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Lomustine | Other | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Doxorubicin. | Other | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Gemcitabine - 21 day cycle | Other | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| 9-ING-41 | Other | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Chemotherapy | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | RECRUITING | NCT06896188 |
| Abraxane | DRUG | Phase PHASE2 | Pancreatic Adenocarcinoma | TERMINATED | NCT05239182 |
| Retifanlimab | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | RECRUITING | NCT06896188 |
| Losartan | DRUG | Phase PHASE2 | Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05077800 |
| FOLFIRNINOX | DRUG | Phase PHASE2 | Pancreatic Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT05077800 |
| Docetaxel | DRUG | Phase PHASE2 | Soft Tissue Sarcoma | WITHDRAWN | NCT05116800 |
| Gemcitabine | DRUG | Phase PHASE2 | Pancreatic Adenocarcinoma | TERMINATED | NCT05239182 |
| Carboplatin | DRUG | Phase PHASE2 | Salivary Gland Cancer | ACTIVE_NOT_RECRUITING | NCT05010629 |
| Topotecan | DRUG | Phase PHASE1 | Refractory Cancer | TERMINATED | NCT04239092 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Refractory Cancer | TERMINATED | NCT04239092 |
| Temozolomide | DRUG | Phase PHASE1 | Refractory Cancer | TERMINATED | NCT04239092 |
| Ruxolitinib | DRUG | Phase PHASE2 | Myelofibrosis | COMPLETED | NCT04218071 |
| Irinotecan | DRUG | Phase PHASE1 | Refractory Cancer | TERMINATED | NCT04239092 |
| Gemcitabine - 28 day cycle | DRUG | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Paclitaxel. | DRUG | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Nab paclitaxel. | DRUG | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Carboplatin. | DRUG | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Lomustine | DRUG | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Doxorubicin. | DRUG | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| Gemcitabine - 21 day cycle | DRUG | Phase PHASE2 | Cancer | ACTIVE_NOT_RECRUITING | NCT03678883 |
| 9-ING-41 | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | RECRUITING | NCT06896188 |